Lantheus Holdings, Inc. key statistics and ratios
In fiscal 2025, Lantheus Holdings, Inc. had return on equity of 21.4%, an operating margin of 20.2%, debt equal to 52.2% of equity and a current ratio of 2.70. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 27.3% | 41.6% | 46.2% | 45.6% | 48.9% | 50.9% | 50.3% | 40.9% | 44.1% | 62.2% | 54.7% | 64.4% | 61.1% | 60.1% |
| Operating margin | −6.7% | 13.1% | 14.5% | 18.7% | 15.6% | 18.8% | 14.9% | −1.2% | −14.3% | 3.9% | 28.1% | 29.8% | 20.2% | 19.4% |
| Net margin | −21.7% | −1.2% | −5.0% | 8.9% | 37.2% | 11.8% | 9.1% | −4.0% | −16.8% | 3.0% | 25.2% | 20.4% | 15.2% | 17.7% |
| Free-cash-flow margin | −7.3% | 1.1% | 2.9% | 14.0% | 11.2% | 12.0% | 16.8% | 4.8% | 12.7% | 2.3% | 20.0% | 32.1% | 23.0% | 24.9% |
| Return on equity | — | — | — | — | — | 85.9% | 34.1% | −4.3% | −14.6% | 6.2% | 51.7% | 32.8% | 21.4% | 22.9% |
| Return on assets | — | −1.5% | −6.1% | 10.7% | 38.6% | 9.8% | 7.5% | −2.1% | −8.2% | 2.6% | 22.0% | 17.2% | 11.1% | 11.9% |
| Asset turnover | — | 1.24 | 1.21 | 1.21 | 1.04 | 0.83 | 0.82 | 0.53 | 0.49 | 0.86 | 0.87 | 0.84 | 0.73 | 0.67 |
| Current ratio | — | 1.67 | 2.53 | 2.53 | 3.16 | 3.70 | 2.62 | 2.29 | 2.61 | 2.74 | 5.80 | 5.52 | 2.70 | 3.06 |
| Debt to equity | — | — | — | — | >999% | 375.3% | 170.2% | 42.5% | 37.7% | 128.6% | 70.5% | 52.0% | 52.2% | 43.5% |
| Interest cover (operating income ÷ interest) | n/m | 0.9x | 1.1x | 2.1x | 2.8x | 3.7x | 3.8x | n/m | n/m | 5.0x | 18.2x | 23.2x | 15.7x | 15.3x |
| Effective tax rate | — | — | — | 5.4% | — | 18.2% | −10.6% | — | — | −5.0% | 20.5% | 27.5% | 25.6% | 24.2% |
| R&D as % of revenue | 10.7% | 4.5% | 4.9% | 4.0% | 5.5% | 5.0% | 5.8% | 9.7% | 10.6% | 33.3% | 6.0% | 11.0% | 11.5% | 11.1% |
| Capital spending as % of revenue | 1.8% | 2.7% | 4.5% | 2.5% | 5.3% | 5.9% | 6.4% | 0.0% | 0.0% | 27.8% | 3.5% | 3.4% | 2.3% | 1.6% |
| Free cash flow ÷ net income | — | — | — | 157.9% | 30.2% | 101.3% | 184.2% | — | — | 77.6% | 79.6% | 157.8% | 151.6% | 140.9% |
| Dividends and buybacks ÷ free cash flow | — | — | — | — | — | — | — | 0.0% | 0.0% | 344.3% | 0.0% | 20.3% | 84.7% | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 63.9% | 63.5% | 63.8% | 63.8% | 57.9% | 59.2% | 61.2% | 62.3% |
| Operating margin | 35.3% | 29.1% | 27.4% | 23.3% | 11.4% | 19.0% | 21.6% | 25.8% |
| Net margin | 34.6% | −3.0% | 19.6% | 20.8% | 7.2% | 13.3% | 31.4% | 19.3% |
| Free-cash-flow margin | 42.0% | 36.1% | 26.5% | 20.9% | 24.7% | 20.0% | 32.3% | 23.2% |
| Current ratio | 1.65 | 5.52 | 5.74 | 4.29 | 2.67 | 2.70 | 2.83 | 3.06 |
| Debt to equity | 47.9% | 52.0% | 48.7% | 48.7% | 50.8% | 52.2% | 47.1% | 43.5% |
| R&D as % of revenue | 6.4% | 9.0% | 9.7% | 12.0% | 12.5% | 11.7% | 10.4% | 9.8% |
Financial health
- Short-term assets cover short-term liabilities $1.0bn of assets due within a year against $336m of liabilities due within a year.
- Short-term assets cover long-term liabilities $1.0bn short-term assets against $767m of longer-dated liabilities.
- More cash than debt $593m of cash against $571m of debt.
- Debt below 40% of shareholders' equity Debt is 44% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 35% to 44% over five years.
- A year's operating cash flow covers at least 20% of debt $413m of operating cash flow against $571m of debt.
- Operating profit covers interest at least five times over Operating income of $302m against $20m of interest.
Moat
Moderate moat
How hard Lantheus Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 20 / 20
Cash operating profit has been a median 20.4% of total assets over 10 years.
- Pricing power 13 / 20
Gross margin has been a median 51.9%, moving by 7.1 percentage points (standard deviation) across 10 years.
- Durability 5 / 20
Operating margin has been a median 16.6%; its worst year was -4.5%.
- Cash conversion 16 / 20
Free cash flow was positive in 9 of 10 years, at a median 13.2% of revenue.
- Discipline 15 / 20
The diluted share count fell 1.2% over five years; stock-based pay has been a median 3.7% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (68 before it).
Compare with peers
- Phibro Animal Health Corp statistics
- Indivior Pharmaceuticals, Inc. statistics
- Trulieve Cannabis Corp. statistics
- Prestige Consumer Healthcare Inc. statistics
- ANI Pharmaceuticals Inc statistics
Head to head: LNTH vs PAHCINDV vs LNTHLNTH vs TRLV
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies